Kevin W. Garey

University of Houston College of Pharmacy

United States

Research Interests

Explore related searches

Professors in United States Professors in Microbiology Microbiology professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (30)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Collaborators (9)

Masaad Saeed Almutairi

SAUDI ARABIA

View details

Taryn Eubank

Research Assistant Professor

University of Houston

UNITED STATES

View details

Vincent Young

Professor

University of Michigan Medical School

UNITED STATES

View details

Hubert C. Chua

Assistant Professor of Pharmacy Practice

Long Island University

UNITED STATES

View details

Robert Britton

Professor

Baylor College of Medicine

UNITED STATES

View details

Travis Carlson

Clinical Assistant Professor

University of Texas at Austin

UNITED STATES

View details

Thomas Riley

Professor of Microbiology

Edith Cowan University

AUSTRALIA

View details

Mark Wilcox

UNITED KINGDOM

View details

Nicholas Rebold

Clinical Assistant Professor

Howard University

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Kevin W. Garey

Research Interests

Explore related searches

Contact this professor

Articles (30)

Prebiotics Improve Blood Pressure Control by Modulating Gut Microbiome Composition and Function: A Systematic Review and Meta-Analysis

Clostridioides difficile is a bacterial priority pathogen

Clostridioides difficile should be considered a bacterial priority pathogen

The impact of ibezapolstat and other Clostridioides difficile infection-relevant antibiotics on the microbiome of humanized mice

The microbiome-restorative potential of ibezapolstat for the treatment of Clostridioides difficile infection is predicted through variant PolC-type DNA polymerase III in Lachnospiraceae and Oscillospiraceae

Real-World Applications of Imipenem-Cilastatin-Relebactam: Insights From a Multicenter Observational Cohort Study

Emerging Clostridioides difficile ribotypes have divergent metabolic phenotypes

Microbiome-Based Therapeutics for Salt-Sensitive Hypertension: A Scoping Review

Phase I trial comparing bile acid and short-chain fatty acid alterations in stool collected from human subjects treated with omadacycline or vancomycin

Defining Fulminant Clostridioides difficile Infections: Assessing the Utility of Hypotension as a Diagnostic Criterion

A Randomized, Double-Blind, Phase 3 Safety and Efficacy Study of Ridinilazole Versus Vancomycin for Treatment of <i>Clostridioides difficile</i> Infection: Clinical Outcomes With Microbiome and Metabolome Correlates of Response

Antibacterial activity of ibezapolstat against antimicrobial-resistant clinical strains of <i>Clostridioides difficile</i>

Microscopy methods for Clostridioides difficile

Development and validation of LC-MS/MS for quantifying omadacycline from stool for gut microbiome studies

Efficacy and Health-Related Quality of Life Impact of Fecal Microbiota, Live-jslm: A Post Hoc Analysis of PUNCH CD3 Patients at First Recurrence of Clostridioides difficile Infection

Erratum to “Development and validation of LC-MS/MS for quantifying omadacycline from stool for gut microbiome studies” (Journal of Chromatography B (2024) 1236, (S1570023224000655), (10.1016/j.jchromb.2024.124057))

Estimating Clostridioides difficile infection-associated readmission rates: A systematic review and meta-analysis

Healthcare Resource Utilization and Discharge Readiness in Adult Hospitalized Patients With Candidemia or Invasive Candidiasis Who Received an Echinocandin: An Analysis of United States Hospitals

Increased Prevalence of Clostridioides difficile Infection among Pediatric Oncology Patients: Risk Factors for Infection and Complications

Reduced Vancomycin Susceptibility in Clostridioides difficile Is Associated With Lower Rates of Initial Cure and Sustained Clinical Response

Gut microbiota changes associated with Clostridioides difficile infection and its various treatment strategies

Emerging Options for the Prevention and Management of Clostridioides difficile Infection

Effect of Fecal Microbiota, Live-Jslm (REBYOTA [RBL]) on Health-Related Quality of Life in Patients With Recurrent Clostridioides difficile Infection: Results From the PUNCH CD3 Clinical Trial

Micafungin pharmacodynamics predict clinical outcomes in hospitalized patients with candidemia caused by certain Candida species

Nonmammalian models to study Clostridioides difficile infection; a systematic review

Development of the invasive candidiasis discharge [I Can discharge] model: a mixed methods analysis

Efficacy, Safety, Pharmacokinetics, and Microbiome Changes of Ibezapolstat in Adults with Clostridioides difficile Infection: A Phase 2a Multicenter Clinical Trial

Functional and Metagenomic Evaluation of Ibezapolstat for Early Evaluation of Anti-Recurrence Effects in Clostridioides difficile Infection

A Vancomycin HPLC Assay for Use in Gut Microbiome Research

Genetic Mechanisms of Vancomycin Resistance in Clostridioides difficile: A Systematic Review

Collaborators (9)

Masaad Saeed Almutairi

Taryn Eubank

Vincent Young

Hubert C. Chua

Robert Britton

Travis Carlson

Thomas Riley

Mark Wilcox

Nicholas Rebold

Make your next move.